Gene therapy for carcinoma of the breast pro-apoptotic gene therapy

Breast Cancer Research

Volumn 2, Issue 1, 2000, Pages 32-44

  Gómez Navarro, Jesús ^a   Arafat, Waleed ^a   Xiang, Jialing ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Breast cancer; Gene therapy

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; CASPASE; DNA; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C RECEPTOR; VIRUS PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL INVASION; CELL SURVIVAL; CLINICAL TRIAL; CORRELATION FUNCTION; DNA DAMAGE; DNA MODIFICATION; DNA VECTOR; DOCUMENTATION; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MEDIATOR; METABOLIC PARAMETERS; MOLECULE; MOUSE; NONHUMAN; ONCOGENE C ERB; PATHOLOGY; PHENOTYPE; REGULATORY MECHANISM; REVIEW;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; FEMALE; GENE THERAPY; HUMANS;

EID: 0034469446     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr27     Document Type: Review

References (144)

1. A matter of life and cell death
2. Apoptosis in cancer therapy: Crossing the threshold
3. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis
4. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
5. Radiosensitization and apoptosis
6. Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95
7. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
8. Apoptosis. Its significance in cancer and cancer therapy
9. Programmed cell death: Apoptosis and oncogenesis
10. Dr. Josef Steiner Cancer Research Prize Lecture: The role of physiological cell death in neoplastic transformation and in anti-cancer therapy
11. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast
12. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage
13. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells
14. Evidence for a function of death-receptor-related, death-domain-containing proteins in anoikis
15. Apoptosis and the dilemma of cancer chemotherapy
16. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis
17. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels
18. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis
19. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
20. Apoptosis and therapy
21. The biochemistry of programmed cell death
22. Molecular pathology of breast cancer and its application to clinical management
23. Apoptosis and angiogenesis: Two promising tumor markers in breast cancer
24. The genetics of sporadic breast cancer
25. Growth factors in breast cancer
26. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells
27. Insulin-like growth factor (IGF)-1 rescues breast cancer cells from chemotherapy-induced cell death: Proliferative and anti-apoptotic effects
28. Gene therapy strategies for carcinoma of the breast
29. Gene therapy for breast cancer
30. The p53 tumor suppressor gene in breast cancer
31. Prognostic value of TP53 protein accumulation in human primary breast cancer: An analysis by luminometric immunoassay on 1491 tumor cytosols
32. Tumour biology. p53, guardian of Rb
33. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
34. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines
35. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma
36. Regulators of apoptosis in human breast cancer
37. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions
38. Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer. South-East Sweden Breast Cancer Group
39. Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas
40. Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas
41. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
42. Bcl-2 protein expression and long-term survival in breast cancer
43. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
44. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers
45. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity
46. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis
47. Apoptosis during breast carcinoma progression
48. bcl-2 protein in invasive ductal breast carcinomas
49. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
50. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer
51. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases
52. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
53. Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up
54. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis
55. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice
56. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction
57. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
58. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases
59. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
60. Caspases: Enemies within
61. Tumor necrosis factor receptor and Fas signaling mechanisms
62. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
63. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
64. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death
65. CD95 ligand expression in dedifferentiated breast cancer
66. Escaping cell death: Survival proteins in cancer
67. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
68. IAP family proteins: Suppressors of apoptosis
69. A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma
70. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
71. Control of apoptosis and mitotic spindle checkpoint by survivin
72. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: Prognostic implications
73. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified
74. Heat shock proteins and cell proliferation in human breast cancer biopsy samples
75. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy
76. The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer
77. Heat shock proteins hsp27 and hsp70: Lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study)
78. Mitochondria and apoptosis
79. Death receptors: Signaling and modulation
80. Caspases: Enemies within
81. Cell death and cancer: Replacement of apoptotic genes and inactivation of death suppressor genes in therapy
82. Apoptosis as a goal of cancer gene therapy
83. P53 and induction of apoptosis as a target for anticancer therapy
84. P53 tumor suppressor gene therapy for cancer
85. Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging
86. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
87. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models
88. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers
89. Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
90. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
91. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
92. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer
93. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
94. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism
95. E1A oncogene-induced cellular sensitization to immune-mediated apoptosis is independent of p53 and resistant to blockade by E1B 19 kDa protein
96. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells
97. Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration
98. Feasibility of adenovirus-mediated gene transfer in vivo
99. Adenovirus-mediated in vivo gene transfer
100. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
101. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice
102. Systemic gene therapy with p53 inhibits breast cancer: Recent advances and therapeutic implications
103. Method for multiple portal vein infusions in mice: Quantitation of adenovirus-mediated hepatic gene transfer
104. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer
105. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
106. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
107. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors
108. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
109. Strategies to adapt adenoviral vectors for gene therapy applications: Targeting and integration
110. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
111. Induction of the growth inhibitor IGF-binding protein 3 by p53
112. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
113. Tat-mediated delivery of heterologous proteins into cells
114. In vivo protein transduction: Delivery of a biologically active protein into the mouse
115. Intercellular delivery of functional p53 by the herpesvirus protein VP22
116. Intercellular trafficking and protein delivery by a herpesvirus structural protein
117. Assays for non-invasive imaging of reporter gene expression
118. Real-time quantitative polymerase chain reaction to assess gene transfer
119. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector
120. Targeted gene therapy
121. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer
122. Deciphering the pathways of life and death
123. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
124. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer
125. Adenoviral vector-mediated expression of Bax selectively induces apoptosis in ovarian cancer cells
126. Tumor radiosensitivity and apoptosis
127. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer
128. Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB
129. A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis
130. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2
131. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7
132. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting
133. Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP) expression in tumor cells
134. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice
135. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
136. A recombinant bcl-xs adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells
137. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
138. bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice
139. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells
140. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene
141. Induction of apoptosis by the tumor suppressor protein BRCA1
142. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis
143. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer